Archive for PARP

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors